A subanalysis of the NeflgArd study shows benefits in eGFR and urine protein-creatinine ratio at baseline and across ...

Two new studies on NEFECON® demonstrate its treatment benefit in the 'Treat Early' strategy for IgA nephropathy (IgAN), providing robust support for the new disease management strategy: 'Treat the ...